GEA Lyophil, part of GEA Pharma Systems, has won a milestone order
from the Zhejiang Hisun Pharmaceutical Co. Ltd. in Taizhou Zhejiang, China for
the supply of pharmaceutical freeze dryers with automatic load and unload
systems (ALUS®). The order is a major breakthrough in the
region allowing Hisun to expand its operations into formulated pharmaceutical
products for injection focus in oncology and infective diseases.
The order was signed on 1st July 2009 at the Hisun
headquarters. GEA Lyophil GmbH will supply seven freeze drying systems and five
ALUS systems with a total value in excess of 15 million euro. The equipment
will be used at the new facilities in the Fuyang pharmaceutical valley and will
allow Hisun to focus on the production of anti-tumour, anti-infective, general
biologics and anti-TB product for both the domestic and export markets. Hisun
is planning to invest over 100 million euro in the Fuyang facility making it
one of the biggest pharmaceutical production sites in China.
GEA Lyophil is the technology leader for pharmaceutical freeze drying and ALUS® systems; this new order will help cement its leading
role in China in the future. GEA Pharma Systems already holds an established
position in China with a major manufacturing facility in Shanghai and an
engineering, service and after-sales structure throughout the country.
GEA Lyophil won the Hisun contract because of its technical excellence,
reputation for operational reliability and proven capability of running large
engineering projects for the pharmaceutical industry.
Hisun has been a
leading pharmaceutical manufacturer in China for over 50 years specialising in
the production of APIs for antibiotics and oncology products. Its products
include anti-infection, anti-parasite, endocrine regulation, immunosuppressant
and antidepressant drugs. The company is one of the biggest players in China:
home to one of the world’s fastest-growing pharmaceutical industries. Hisun
exports more than 80% of its products and holds a leading market position in
over 30 countries in the Far East, Europe and the USA.
The Chinese
pharmaceutical industry is investing heavily in top quality production
technology both for domestic and export pharmaceuticals. This recent order for
GEA Lyophil is a clear illustration of this trend.
All business enquiries to:
Hubert Kluetsch
Director Sales
& Marketing
GEA Lyophil GmbH
Tel: +49 (0) 2233/6999-220
Fax: +49 (0) 2233/6999-8220
Email: Hubert.Kluetsch@geagroup.com
For further editorial information contact:
Sharon Lyons
GEA Pharma Systems
Tel: +32 3 350 12
41
Email: sharon.lyons@geagroup.com